HMPL004-6599 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	1
97	Ulcerative colitis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03597971 (ClinicalTrials.gov)	March 20, 2018	3/5/2018	HMPL004-6599 Phase I Dose-escalating Study	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL004-6599 in Healthy Male Volunteers	Ulcerative Colitis;Crohn Disease	Drug: HMPL004-6599;Drug: Placebo	Nutrition Science Partners Limited	Hutchison Medipharma Limited;Nestlé	Terminated	18 Years	45 Years	Male	32	Phase 1	Australia

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03597971 (ClinicalTrials.gov)	March 20, 2018	3/5/2018	HMPL004-6599 Phase I Dose-escalating Study	A Phase I, Randomized, Double Blind, Placebo-controlled, Dose-escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of HMPL004-6599 in Healthy Male Volunteers	Ulcerative Colitis;Crohn Disease	Drug: HMPL004-6599;Drug: Placebo	Nutrition Science Partners Limited	Hutchison Medipharma Limited;Nestlé	Terminated	18 Years	45 Years	Male	32	Phase 1	Australia